OP0212 Endothelin-1 induces a profibrotic phenotype in cultured human microvascular endothelial and circulating monocyte/macrophage cells
BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in s...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 76; no. Suppl 2; p. 140 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier Limited
01.06.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 0003-4967 1468-2060 |
DOI | 10.1136/annrheumdis-2017-eular.4317 |
Cover
Loading…
Abstract | BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc.ObjectivesTo investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages.MethodsHMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1.Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1.Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers –α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) – were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test.ResultsIn cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells).In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types.ConclusionsET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment.References Wynn TA et al. Immunity. 2016;44:450–62. Disclosure of InterestS. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion |
---|---|
AbstractList | BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc.ObjectivesTo investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages.MethodsHMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1.Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1.Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers –α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) – were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test.ResultsIn cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells).In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types.ConclusionsET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment.ReferencesWynn TA et al. Immunity. 2016;44:450–62.Disclosure of InterestS. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc.ObjectivesTo investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages.MethodsHMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1.Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1.Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers –α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) – were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test.ResultsIn cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells).In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types.ConclusionsET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment.References Wynn TA et al. Immunity. 2016;44:450–62. Disclosure of InterestS. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion Background The alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by the transition of these cell types into a profibrotic phenotype, represent early and crucial pathological features of the fibrotic process in systemic sclerosis (SSc) (1). The alternatively activated macrophage subset M2a was found in several diseases characterized by extensive fibrosis (1). M2a macrophages express specific phenotype markers, CD206 (mannose receptor), CD204 and CD163 (scavenger receptors) as well as profibrotic molecules, primarily transforming growth factor-β1 (TGFβ1) (1). Endothelin-1 (ET1) and/or TGFβ1 are known to induce the transition of fibroblasts into profibrotic myofibroblasts, which are key mediators of fibrosis in SSc. Objectives To investigate the effects of ET1 in inducing a profibrotic phenotype in cultured human microvascular ECs (HMVECs) and macrophages. Methods HMVECs, at 3rd culture passage, were grown in endothelial cell medium (EGM2MV) and treated for 6 days with ET1 (100nM) or treated for 1 hr with ET1 receptor antagonist (ETA/BRA, bosentan 10μM) before stimulation with ET1. Human monocytes were isolated from peripheral blood mononuclear cells of healthy subjects using a monocyte isolation kit. The cells were maintained in RPMI growth medium for 24 hrs and then treated for 6 days with ET1 or treated for 1 hr with bosentan before stimulation with ET1. Cultured HMVECs and monocytes maintained in EGM2MV and RPMI growth medium, respectively, were used as untreated cells. Gene and protein expression of profibrotic myofibroblast markers -α-smooth muscle actin (α-SMA), fibroblast specific protein-1 (S100A4), type 1 collagen (COL1) and fibronectin (FN) - were evaluated by quantitative real time polymerase chain reaction (qRT-PCR), Western blotting (WB) and immunocytochemistry (ICC) in cultured HMVECs. Gene and protein expression of M2a phenotype markers (CD206, CD204, CD163) and TGFβ1 were investigated by qRT-PCR and WB in cultured human macrophages. Statistical analysis was carried out by Mann-Whitney non-parametric test. Results In cultured HMVECs, ET1 induced the significant upregulation of the gene expression of α-SMA, S100A4 (myofibroblast markers), COL1 and FN, compared to untreated cells (p<0.001;p<0.001;p<0.05;p<0.01). ETA/BRA significantly contrasted the ET1 mediated transition of HMVECs into a profibrotic phenotype (p<0.05 for α-SMA, COL1 and FN; p<0.01 for S100A4 vs. ET1-treated cells). In cultured human macrophages, ET1 induced the significant overexpression of M2a markers (p<0.05 for CD204 and CD163;p<0.01 for CD206) and TGFβ1 (p<0.01) compared to untreated cells. ETA/BRA significantly contrasted the ET1-mediated transition of cultured macrophages into profibrotic M2a (p<0.05 vs. ET1-treated cells, for all investigated proteins). Data were confirmed by WB and ICC on both cultured cell types. Conclusions ET1 seems to be involved in the early phases of the fibrotic process by inducing the transition of both cultured HMVECs and macrophages into a profibrotic phenotype, myofibroblast and M2a respectively (observed in SSc), a process which is apparently contrasted by ETA/BRA treatment. ReferencesWynn TA et al. Immunity. 2016;44:450-62. Disclosure of Interest S. Soldano: None declared, P. Montagna: None declared, R. Brizzolara: None declared, A. Trombetta: None declared, A. Sulli: None declared, C. Pizzorni: None declared, M. Ghio: None declared, S. Paolino: None declared, V. Smith: None declared, M. Cutolo Grant/research support from: Actelion |
Author | Soldano, S Paolino, S Pizzorni, C Montagna, P Smith, V Trombetta, AC Cutolo, M Brizzolara, R Sulli, A Ghio, M |
Author_xml | – sequence: 1 givenname: S surname: Soldano fullname: Soldano, S organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 2 givenname: P surname: Montagna fullname: Montagna, P organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 3 givenname: R surname: Brizzolara fullname: Brizzolara, R organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 4 givenname: AC surname: Trombetta fullname: Trombetta, AC organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 5 givenname: A surname: Sulli fullname: Sulli, A organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 6 givenname: C surname: Pizzorni fullname: Pizzorni, C organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 7 givenname: M surname: Ghio fullname: Ghio, M organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 8 givenname: S surname: Paolino fullname: Paolino, S organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy – sequence: 9 givenname: V surname: Smith fullname: Smith, V organization: Department of Rheumatology, Ghent University Hospital, Ghent, Belgium – sequence: 10 givenname: M surname: Cutolo fullname: Cutolo, M organization: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy |
BookMark | eNqVkc1q3TAQhUVJoTdp30GQtZORpSvZdBVC-gOBZNGuhf4c62JLjmQH7i6brvKWeZLKuQ10Fchq0Mw5Mzp8x-goxOAQOiVwRgjl5yqE1LtltD5XNRBRuWVQ6YxRIj6gDWG8KW0OR2gDALRiLRef0HHOu_KEhjQb9HRzCzWpnx__XAUb594NPlQE-2AX4zJWeEqx8zrF2Rs89S7EeT-5MsdmGeYlOYv7ZVQBj96k-KCyWX-A3esyNWAVLDY-rYPZhzs8xhDNfnbnoyqWqVd3Dhs3DPkz-tipIbsv_-oJ-v3t6tflj-r65vvPy4vrStfQiIoQEHoLgjfUAmdcG1bC2baxNelqJTTYljKqGrBW846K1oqOardted1pQ-kJOj3sLdnuF5dnuYtLCuWkrBkjrKW02b6pgqJot_Ci-npQlSg5J9fJKflRpb0kIFdG8j9GcmUkXxjJlVFx84Nbj7t3Gf8CLTqhpw |
ContentType | Journal Article |
Copyright | 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
Copyright_xml | – notice: 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: 2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
DBID | AAYXX CITATION 3V. 7X7 7XB 88E 88I 8AF 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9- K9. LK8 M0R M0S M1P M2P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U |
DOI | 10.1136/annrheumdis-2017-eular.4317 |
DatabaseName | CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database (Proquest) ProQuest Central Natural Science Collection BMJ Journals ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic |
DatabaseTitle | CrossRef ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest Central Student ProQuest Central Student |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
EndPage | 140 |
ExternalDocumentID | 10_1136_annrheumdis_2017_eular_4317 annrheumdis |
GroupedDBID | --- .55 .GJ .VT 169 23M 2WC 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAXUO ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACPRK ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FDB FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP AAFWJ AALRI AAYXX CITATION PHGZM 3V. 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U |
ID | FETCH-LOGICAL-b2087-1107b507683d0646bc4003d98d21f2a7b0d9343a80ddb6f379d7f3be5962fbc33 |
IEDL.DBID | 7X7 |
ISSN | 0003-4967 |
IngestDate | Fri Jul 25 11:04:13 EDT 2025 Fri Jul 25 11:06:28 EDT 2025 Tue Jul 01 00:58:34 EDT 2025 Thu Apr 24 22:50:27 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b2087-1107b507683d0646bc4003d98d21f2a7b0d9343a80ddb6f379d7f3be5962fbc33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
OpenAccessLink | https://ard.bmj.com/content/annrheumdis/76/Suppl_2/140.2.full.pdf |
PQID | 2033895085 |
PQPubID | 2041045 |
PageCount | 1 |
ParticipantIDs | proquest_journals_2441493385 proquest_journals_2033895085 crossref_primary_10_1136_annrheumdis_2017_eular_4317 bmj_primary_10_1136_annrheumdis_2017_eular_4317 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20170600 2017-06-00 20170601 |
PublicationDateYYYYMMDD | 2017-06-01 |
PublicationDate_xml | – month: 06 year: 2017 text: 20170600 |
PublicationDecade | 2010 |
PublicationPlace | Kidlington |
PublicationPlace_xml | – name: Kidlington |
PublicationTitle | Annals of the rheumatic diseases |
PublicationYear | 2017 |
Publisher | Elsevier Limited |
Publisher_xml | – name: Elsevier Limited |
SSID | ssj0000818 |
Score | 2.2156694 |
Snippet | BackgroundThe alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by... Background The alteration of microvascular endothelial cell (EC) functions and the presence of macrophages in the immune inflammatory infiltrate, followed by... |
SourceID | proquest crossref bmj |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 140 |
SubjectTerms | Actin Caregivers CD163 antigen Cell culture Collagen Comorbidity Councils Culture media Endothelial cells Endothelin 1 Endothelins Fibroblasts Fibronectin Fibrosis Gene expression Genotype & phenotype Immunocytochemistry Inflammation Investigations Leukocytes (mononuclear) Macrophages Mannose Mental depression Microvasculature Monocytes Peripheral blood mononuclear cells Phenotypes Polymerase chain reaction Protein expression Proteins Rheumatoid arthritis Rheumatology S100A4 protein Scleroderma Sclerosis Smooth muscle Statistical analysis Transforming growth factor-b1 Western blotting |
Title | OP0212 Endothelin-1 induces a profibrotic phenotype in cultured human microvascular endothelial and circulating monocyte/macrophage cells |
URI | https://ard.bmj.com/content/76/Suppl_2/140.2.full https://www.proquest.com/docview/2033895085 https://www.proquest.com/docview/2441493385 |
Volume | 76 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1JSwMxFA7aQvEirrhUCeh17JJkZnISlZYitBax0NuQrS7QGe1y8ObFk__SX-J76YxSEMFzZoF8L2_Le-8j5DSWwoBbqwLFdRTwWPJAGTcKpDSiblykBMN-524v7Az49VAM84TbNC-rLHSiV9Q2M5gjr4EZAmceAipx_vwSIGsU3q7mFBqrpIyjyzD4iobRjyaOG3HBmMdlGFXISc5igiQvkwc3H9vHKQgKaGqHVZ9naE7Byujx07KdWlbT3va0N8h67jTSiwXKm2TFpVuk0s2vxbfJx00fZ6h_vr23UostVeA7Bg0K4TYAN6WKemZuPcngfYpFXRlmXmGdLgZvOEs9Vx8dY3leUZxKXfEx-LdKLTWPE-PZvtJ7CtuRmdeZq40VkoA9gFqieAkw3SGDduvuqhPkLAuBbtZBw2AAqAVeyDEL_kmoDRxrZmVsm41RU0W6biXjTMV1iy17LJI2GjHtkLZnpA1ju6SUZqnbI9QKCOZibnUsJDc61IC4CSWz1jaFE3yf1GBnk-fFHI3Exx_M90QXWCSIReKxSBCLfcILFP73WrVALMnPJD4D0oOkt-L35W8BO_h7-ZCseYnxqZgqKc0mc3cEnslMH3vxOybly1avf_sFE0znyQ |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1NTxRBEK0QTNCLET8iitCJchx3drp7ZvpgjBHIIix4gGRvQ38tLMnOrLtLDDcunPwv_ih_iVW90xoSY8KBc0_PJF1v6lV1V_UDeFcqaTGs1YkWpkhEqUSirR8mSlmZWl9oyanfuX-Y907El4EcLMHP2AtDZZXRJwZH7RpLe-QdpCEM5jGhkh8n3xJSjaLT1SihsYDFvr_6jinb7MPeNtp3K8t2d44_95JWVSAxWYp_FCU8RtIBFHfIx7mxCGPuVOmy7jDThUmd4oLrMnXUosYL5YohN55kaobG0gYouvwHSLwplRAWg-Kv5y-7ZVToEyovVuBtq5pCojLTc385dqMZAhOZwVOV6Xuib2Q1M764zYu3aSFw3e4TeNwGqezTAlWrsOTrp7DSb4_hn8GPo690Z_uv65ud2lELF8aqSZdheo9AmTHNghK4mTY4n1ERWUM7vTjOFhd9eMeCNiAbUzlgLIZlPr4Mv61rx-xoaoO6WH3GcPkbezX3nbEm0bFzdIOMDh1mz-HkXtb_BSzXTe1fAnMSk8dSOFNKJazJDSLM5oo75zLppViDDq5sNVnc21GFfIeHHuxoi4psUQVbVGSLNRDRCnebth4tVrU-gJ5BtJLIrvz38B9Av_r_8CY87B33D6qDvcP91_AooCdsA63D8nx66d9gVDQ3GwGKDE7vG_u_AbHPIY8 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LaxRBEC5ChMWLaFRMjKZBPY67O909PX0QEZMlDxNzMLC3sV-TB-xM3N0guXnJKf_In-Mvsap3WgmIkEPOPQ_o-rq-qu6q_gBel1o6DGtNZoRVmSi1yIwLdaa1kwMXlJGc-p33D4rtI7E7luMl-Jl6YaisMvnE6Kh962iPvI80hME8JlSyX3dlEYebo_fn3zJSkKKT1iSnsYDIXrj8junb7N3OJtr6TZ6Ptr583M46hYHM5gNcXZT8WEmHUdwjNxfWIaS516XPh3VulB14zQU35cBTuxpX2qua20CSNbV1tBmK7v-e4kibuJbUWP1lgXJYJrU-oQvVg1edggoJzExPwsXEn84QpMgSgSpO3xKVI8PZydlNjrxJEZH3Rg_hQRewsg8LhD2CpdCsQG-_O5J_DNefD-n-9l8_rrYaT-1cGLdmQ4apPoJmxgyLquB22uL7jArKWtr1xXG2uPQjeBZ1AtmESgNTYSwL6WP4b9N45k6nLiqNNccMp791l_PQnxgSIDtBl8joAGL2BI7uZP6fwnLTNuEZMC8xkSyFt6XUwtnCItpcobn3PpdBilXo48xW54s7PKqY-_DYj51sUZEtqmiLimyxCiJZ4XavrSeLVZ0_oGcQuSS4K_89_Afca_8f3oAeor76tHOw9xzuR_DEHaF1WJ5PL8ILDJDm9mVEIoOvdw393-WaJcU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OP0212%E2%80%85Endothelin-1+induces+a+profibrotic+phenotype+in+cultured+human+microvascular+endothelial+and+circulating+monocyte%2Fmacrophage+cells&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Soldano%2C+S&rft.au=Montagna%2C+P&rft.au=Brizzolara%2C+R&rft.au=Trombetta%2C+A+C&rft.date=2017-06-01&rft.pub=Elsevier+Limited&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=76&rft.spage=140&rft.epage=140&rft_id=info:doi/10.1136%2Fannrheumdis-2017-eular.4317&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |